Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a nerve channel blocker replace opioids? early study investigates

NCT ID NCT07511400

Knowledge-focused Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called suzetrigine, which blocks a specific nerve channel (NaV1.8) involved in pain signaling. In 67 healthy volunteers, tiny amounts were injected into the skin alongside a placebo and lidocaine. Participants received six different types of brief pain (electrical, mechanical, chemical, heat, cold, acid) to see which ones the drug could reduce. The goal is to understand which pain types depend on NaV1.8, potentially guiding development of new, non-opioid pain treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Suzetrigine (a selective NaV1.8 blocker) and lidocaine (a standard local anesthetic)
What this could lead to
If successful, this study could help identify which types of pain are best treated by targeting NaV1.8, paving the way for new non-opioid pain medications.
What could go wrong
This is a very early, small study in healthy volunteers using tiny doses injected into the skin. Results may not apply to real-world pain or lead directly to a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

67 people

The number who actually took part.

Started

Apr 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age between 18 and 70 years * Full legal capacity Exclusion criteria * Participant of another study, ongoing or within the last 4 weeks * Medication intake (except contraception) or drug abuse * Female subjects: Positive pregnancy test or breastfeeding * Verified body temperature above 38°C * Known allergic diseases, in particular asthmatic disorders * Limited accessibility of forearms (e.g. orthopedic cast) * Sensory deficit, skin disease or hematoma at the forarms

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute Pain common cold Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain Healthy volunteer study Pain

Contacts and locations

Locations

  • Medical University of Vienna

    Vienna, State of Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.